Review
Jul 2026
KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable.
New direct inhibitor classes have emerged recently, including tri-complex ON-state inhibitors and dual-state ON/OFF inhibitors capable of targeting not only KRASG12C but also other KRAS mutations, as well as panKRAS and panRAS strategies.
Tämer El Saadany, Núria Aeschlimann, A. Sacher
· Cancer Journal · 0 citations